Providence Regional Cancer System

Lacey, Washington 98503

3 studies enrolling now · 9 studies all time

What they study most

Breast Cancer, Castration-resistant Prostate Cancer, Colorectal Neoplasms, Early Breast Cancer, Metastatic Non Small Cell Lung Cancer, Prostate Cancer Metastatic, Prostatic Neoplasms, Solid Tumor and Hematologic Malignancies, Triple Negative Breast Cancer

Studies at this site

• A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy — Recruiting now
• Phase IIIb Study of Ribociclib + ET in Early Breast Cancer — Recruiting now
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) — Recruiting now
• Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) — Running, not enrolling
• Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations — Running, not enrolling
• HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Stopped early
• Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer — Completed
• MEK162 for Patients With RAS/RAF/MEK Activated Tumors — Completed
• Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer — Completed